ProMIS Neurosciences Inc - Company Profile
Powered by 
All the sales intelligence you need on ProMIS Neurosciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how ProMIS Neurosciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with ProMIS Neurosciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies for neurodegenerative diseases caused by abnormal, misfolded proteins. The company targets conditions such as multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer’s disease, where toxic protein conformations drive disease progression. Its lead program, PMN310, is a monoclonal antibody being developed for Alzheimer’s disease. ProMIS uses a patented technology platform to design antibody candidates that selectively recognize and neutralize toxic forms of proteins while avoiding interference with the normal, healthy proteins required for cellular function. ProMIS is headquartered in Toronto, Ontario, Canada.
Headquarters
Canada
Address
Suite 200, 1920 Yonge Street, Toronto, Ontario, M4S3E2
Website
www.promisneurosciences.com
Telephone
1 416 8476898
No of Employees
6
Industry
Medical Equipment
Ticker Symbol & Exchange
PMN (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-1529.3%
(2024 vs 2023)
Market Cap*
$125.5M
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
ProMIS Neurosciences Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline: | Diagnostic Services | ProMIS |
| PMN310 (Alzheimer's Disease) | ||
| PMN442 (Multiple System Atrophy) | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In May, the company announced FDA Clearance for Investigation of New Drug Application for PMN310 in Alzheimer’s Disease. |
| 2023 | Others | In March, the company’s Lead Therapeutic candidate PMN310, Demonstrated Enhanced Selectivity for Toxic Oligomers compared to other Amyloid -Beta-Directed Antibodies. |
| 2022 | Others | In January, the company announced antibody program for schizophrenia therapy. |
Competitor Comparison
| Key Parameters | ProMIS Neurosciences Inc | Eli Lilly and Co | AbbVie Inc | Novartis AG | Takeda Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | Switzerland | Japan |
| City | Toronto | Indianapolis | North Chicago | Basel | Chuo-Ku |
| State/Province | Ontario | Indiana | Illinois | Basel-Stadt | Tokyo |
| No. of Employees | 6 | 50,605 | 57,000 | 75,267 | 47,455 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eugene Williams | Chairman | Executive Board | 2015 | 66 |
| Neil K. Warma | Chief Executive Officer; Director; President | Executive Board | 2024 | 63 |
| Neil Cashman, M.D. | Chief Scientific Officer; Director | Executive Board | 2014 | 74 |
| Daniel E. Geffken | Chief Financial Officer | Senior Management | 2017 | 69 |
| Larry Altstiel, M.D., Ph.D. | Chief Medical Officer | Senior Management | 2022 | 76 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer